Rapid Effects of Rosiglitazone Treatment on Endothelial Function and Inflammatory Biomarkers
- 1 September 2005
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 25 (9), 1804-1809
- https://doi.org/10.1161/01.atv.0000176192.16951.9a
Abstract
Background— Antidiabetic thiazolidinediones (TZDs), like rosiglitazone or pioglitazone, improve endothelial function in patients with type 2 diabetes or metabolic syndrome, but it is currently unknown, whether these beneficial effects of TZDs depend on their metabolic action or may be caused by direct effects on the endothelium. Therefore, the present study examined whether short-term rosiglitazone treatment influences endothelium-dependent vasodilation as well as serum levels of vascular disease biomarkers in healthy, nondiabetic subjects. Methods and Results— Short-term treatment (21 days) of healthy subjects (n=10) did not significantly change blood glucose levels or lipid profile. In contrast, rosiglitazone significantly increased flow-mediated, endothelium-dependent vasodilation already within the first day from 5.3±2.7% at baseline to 7.8±2.6%, further increasing it to 9.4±3.0% at day 21. In addition, the early improvement of endothelium-dependent vasodilation was paralleled by a rapid reduction of serum levels of the biomarkers C-reactive protein (CRP), serum amyloid A (SAA), and sE-selectin. Moreover, after drug withdrawal all markers remained suppressed for the whole follow-up period of 7 days. In contrast, rosiglitazone treatment did not significantly affect tumor necrosis factor (TNF)-α, interleukin (IL)-6, sICAM-1, sVCAM-1, and sCD40L levels. Conclusions— Our study suggests a direct effect of TZD treatment on endothelial function and inflammatory biomarkers of arteriosclerosis, promoting the concept that TZDs, independent of their metabolic action, may exhibit protective effects in the vessel wall.Keywords
This publication has 29 references indexed in Scilit:
- In Type 2 Diabetes, Rosiglitazone Therapy for Insulin Resistance Ameliorates Endothelial Dysfunction Independent of Glucose ControlDiabetes Care, 2004
- Testing Endothelial Vasomotor FunctionCirculation, 2003
- Endothelial Function Testing as a Biomarker of Vascular DiseaseCirculation, 2003
- Antidiabetic PPARγ-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Endothelial function: From vascular biology to clinical applicationsThe American Journal of Cardiology, 2002
- Prognostic implications of endothelial dysfunction: does it mean anything?Coronary Artery Disease, 2001
- Endothelial function and coronary artery diseaseCurrent Opinion in Lipidology, 2001
- Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitusThe American Journal of Cardiology, 1999
- Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.JCI Insight, 1995
- Vascular EndotheliumAnnals of the New York Academy of Sciences, 1994